PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS
    23.
    发明公开
    PROCESSES FOR THE PREPARATION OF SGLT2 INHIBITORS 有权
    制备SGLT2抑制剂的过程

    公开(公告)号:EP2324002A2

    公开(公告)日:2011-05-25

    申请号:EP09808859.4

    申请日:2009-08-21

    申请人: Theracos, Inc.

    摘要: Provided are processes for the preparation of complexes that are useful in purifying compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The processes can reduce the number of steps needed to obtain the target compounds and the complexes formed in the processes are typically provided in a crystalline form.

    摘要翻译: 提供了用于制备可用于纯化对钠依赖性葡萄糖协同转运蛋白SGLT具有抑制作用的化合物的复合物的方法。 该方法可以减少获得目标化合物所需的步骤数,并且在该方法中形成的络合物通常以结晶形式提供。

    BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE
    24.
    发明公开
    BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE 有权
    苄基环己烷衍生物及其使用方法

    公开(公告)号:EP2230907A1

    公开(公告)日:2010-09-29

    申请号:EP08859426.2

    申请日:2008-12-11

    申请人: Theracos, Inc.

    IPC分类号: A01N31/04

    CPC分类号: C07H7/04

    摘要: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.

    摘要翻译: 提供了对钠依赖性葡萄糖协同转运蛋白SGLT具有抑制作用的化合物。 本发明还提供了药物组合物,制备该化合物的方法,合成中间体以及独立地或与其他治疗剂组合使用该化合物用于治疗受SGLT抑制影响的疾病和病症的方法。

    TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS
    26.
    发明公开
    TREATING PSYCHOLOGICAL CONDITIONS USING MUSCARINIC RECEPTOR M1 ANTAGONISTS 有权
    用麦考酚酸受体M1拮抗剂治疗心理状况

    公开(公告)号:EP2032127A1

    公开(公告)日:2009-03-11

    申请号:EP07784456.1

    申请日:2007-06-15

    申请人: Theracos, Inc.

    IPC分类号: A61K31/00 A61K45/06

    摘要: Provided are methods of treating psychological diseases and conditions by administration of a preferential muscarinic acetylcholine receptor M1 antagonist, optionally with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist. The invention also provides for pharmaceutical compositions and kits for administration of at least one selective muscarinic acetylcholine receptor M1 antagonist in combination with at least one antidepressant other than a selective muscarinic acetylcholine receptor M1 antagonist.

    摘要翻译: 提供了通过施用优先毒蕈碱乙酰胆碱受体M1拮抗剂,任选地与除选择性毒蕈碱乙酰胆碱受体M1拮抗剂以外的至少一种抗抑郁药治疗心理疾病和病症的方法。 本发明还提供了用于施用至少一种选择性毒蕈碱乙酰胆碱受体M1拮抗剂以及除了选择性毒蕈碱乙酰胆碱受体M1拮抗剂以外的至少一种抗抑郁药的药物组合物和试剂盒。